After administration of a single 60 mg capsule to healthy subjects, the mean maximum plasma concentration (Cmax) was 131 ng/mL. Onset of action for reduction in total symptom scores, excluding nasal congestion, was observed at 60 minutes compared to placebo following a single 60 mg fexofenadine hydrochloride dose administered to subjects with seasonal allergic rhinitis who were exposed to ragweed pollen in an environmental exposure unit.


The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults. Although the number of subjects in some of the subgroups was small, there were no significant differences in the effect of fexofenadine hydrochloride across subgroups of subjects defined by gender, age, and race. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects. Similar reductions were observed for mean number of wheals and mean pruritus score at the end of the 24-hour dosing interval. Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or the result of biliary excretion.
Symptom reduction was greater with fexofenadine hydrochloride180 mg than with placebo. In one 2-week, multicenter, randomized, double-blind clinical trial in subjects 12 to 65 years of age with seasonal allergic rhinitis (n=863), fexofenadine hydrochloride 180 mg once daily significantly reduced total symptom scores (the sum of the individual scores for sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes) compared to placebo. However, no additional benefit of the 120 or 240 mg fexofenadine hydrochloride twice daily dose was seen over the 60 mg twice daily dose in reducing symptom scores. Co-administration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the Allegra D Ingredients area under the curve (AUC) and (Cmax) of fexofenadine by 21 and 20% respectively. Improvement was demonstrated Where To Buy Allegra D 1 day of treatment with fexofenadine hydrochloride 180 mg and was maintained over the entire 4- week treatment period.
In these studies, there was no Allegra D Ingredients reduction in total symptom scores with higher doses of fexofenadine hydrochloride up to 240 mg twice daily. Two 4-week multicenter, randomized, double-blind, placebo-controlled clinical trials compared four different doses of fexofenadine hydrochloride tablet (20, 60, 120, and 240 mg twice daily) to placebo in subjects aged 12 to 70 years with chronic idiopathic urticaria (n=726). Fexofenadine hydrochloride, the major active metabolite Allegra D Ingredients terfenadine, is an antihistamine with selective peripheral H1-receptor antagonist activity. The clinical significance of these findings is unknown. Administration of a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.